Summary Highlights:
- AbbVie (ABBV, Financial) is poised to release its Q1 2025 earnings, with analysts projecting positive growth in both earnings per share (EPS) and revenue.
- The stock has an average analyst price target of $213.68, signaling a potential upside of 18.83% from its current price.
- Despite optimistic projections, market sentiment remains cautious due to broader economic concerns.
AbbVie's Upcoming Earnings Announcement: What to Expect
AbbVie Inc. (NYSE: ABBV) is on the brink of revealing its financial performance for the first quarter of 2025, scheduled before the market opens on April 25. Analysts are forecasting a promising year-over-year increase in earnings per share, estimated at $2.39, alongside anticipated revenue growth reaching $12.92 billion. However, investors are advised to remain vigilant as macroeconomic headwinds could pose risks, leading to tempered market expectations.
Insights from Wall Street Analysts
Market experts have weighed in, offering a range of one-year price targets for AbbVie Inc. (ABBV, Financial), with an average target set at $213.68. This figure includes a high projection of $251.00 and a low of $173.00, suggesting a significant potential upside of 18.83% from the current trading price of $179.83. For an in-depth examination of these estimates, visit the AbbVie Inc (ABBV) Forecast page.
The consensus among 27 brokerage firms places AbbVie at an "Outperform" recommendation, with an average rating of 2.0. This rating is part of a broader scale where 1 indicates a Strong Buy and 5 suggests a Sell.
When considering the GF Value — GuruFocus’ assessment of the stock’s fair market value — AbbVie Inc is projected at $167.84 in one year, which implies a potential downside of 6.66% from the current price of $179.825. This valuation is derived from analyzing historical trading multiples, past business growth, and future performance forecasts. For additional insights, explore the AbbVie Inc (ABBV, Financial) Summary page.
